Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis
Therapeutic Advances in Medical Oncology
Published online on March 11, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The COMPASSION-15 trial showed that cadonilimab plus chemotherapy has significant clinical advantages in patients with HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma compared to chemotherapy. This study ...
Background:The COMPASSION-15 trial showed that cadonilimab plus chemotherapy has significant clinical advantages in patients with HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma compared to chemotherapy. This study ...